Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has received …